6/30/23, 12:47 AM Wang Pathway Feedback Search Clinical Topics Home Studies Wang Wang Disease COVID 19 infection Trial question What is the effect of remdesivir in the treatment of patients hospitalized with severe COVID-19? Study design Multi-center Double blinded RCT Population Characteristics of study participants 41.0% female N = 237 59.0% male 237 patients (96 female, 140 male) Inclusion criteria: adults (aged 18 years) admitted to hospital with laboratory-confirmed COVID-19, with an interval from symptom onset to the enrolment 12 days, oxygen saturation 94% on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen 300 mmHg , and radiologically confirmed pneumonia Key exclusion criteria: hepatic cirrhosis; ALT or AST > 5 times the ULN; known severe renal impairment or receipt of continuous RRT, hemodialysis, or peritoneal dialysis Interventions N=158 remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) N=78 placebo (the same volume of matching placebo infusions for 10 days) Primary outcome Time to clinical improvement up to day 28 23 23 0 d 21 https://web.pathway.md/studies/recEhFFdGWFHtH76p 1/2 6/30/23, 12:47 AM 23.0 days Wang Pathway 21 17.3 days 11.5 days 5.8 days No significant difference 0.0 days Remdesivir Placebo No significant difference in time to clinical improvement up to day 28 (21 days vs. 23 days; HR 0.81, 95% CI 0.57 to 1.15) Secondary outcomes No significant difference in the rate of death by day 28 (14% vs. 13%; AD 1.1%, 95% CI -8.1 to 10.3) Safety outcomes No significant difference in adverse events. Significant differences in serious adverse events (18% vs. 26%), drug discontinuation due to adverse events or serious adverse events (12% vs. 5%). Conclusion In adults (aged 18 years) admitted to hospital with laboratory-confirmed COVID-19, with an interval from symptom onset to the enrolment 12 days, oxygen saturation 94% on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen 300 mmHg , and radiologically confirmed pneumonia, remdesivir was not superior to placebo with respect to time to clinical improvement up to day 28. Reference Yeming Wang, Dingyu Zhang, Guanhua Du et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569-1578. Open reference URL https://web.pathway.md/studies/recEhFFdGWFHtH76p 2/2